Anamorelin patents and clinical trials: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
Anamorelin Study for Advanced Pancreatic Cancer	Helsinn Healthcare SA	Phase 2
Anamorelin Study for Advanced Pancreatic Cancer	Quartesian LLC	Phase 2
Anamorelin Study for Advanced Pancreatic Cancer	Lahey Clinic	Phase 2

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: September 11, 2026

Anamorelin is a selective ghrelin receptor agonist approved in Japan as Adlumiz for cancer cachexia. Its commercial value is established in Japan but remains geographically limited because the drug has not secured U.S. or European approval. The main development risk is clinical: anamorelin improves body weight and lean body mass, but pivotal studies did not show a consistent improvement in muscle strength or physical function. That endpoint gap led to European regulatory failure and remains the central barrier to global expansion.

A reasonable base-case projection is a Japan-centered market of approximately ¥10 billion to ¥25 billion annually at maturity, equivalent to roughly $65 million to $165 million using a ¥150-per-dollar conversion. A global market above $500 million would require successful additional trials and regulatory approvals outside Japan.

What is the current development status of anamorelin?

Anamorelin hydrochloride hydrate is an orally administered, selective ghrelin receptor agonist developed for cancer cachexia. It activates the growth hormone secretagogue receptor and is intended to increase appetite, body weight, and lean body mass.

Item	Current status
Active ingredient	Anamorelin hydrochloride hydrate
Brand	Adlumiz
Developer and Japanese rights holder	Helsinn Healthcare SA and Ono Pharmaceutical
Japanese approval	Approved in 2020
Approved use	Cancer cachexia associated with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer
U.S. status	Not approved
European Union status	Not approved
Administration	Oral tablet, 50 mg strength in Japan
Therapeutic class	Ghrelin receptor agonist
Main clinical benefit	Increased body weight and lean body mass
Main regulatory weakness	Inconsistent evidence for muscle strength and physical function

Japan approved Adlumiz in September 2020 for patients with cancer cachexia when weight loss and reduced appetite are present and the underlying cancer treatment is continuing. The approval was based primarily on improvements in lean body mass and body weight rather than a broad functional recovery endpoint (Ono Pharmaceutical, 2020; Pharmaceuticals and Medical Devices Agency, 2020).

No public development program has established an approved indication in the United States or European Union through the latest widely available regulatory records.

Which clinical trials established anamorelin’s efficacy?

The pivotal evidence came from the ROMANA clinical program, which evaluated patients with non-small cell lung cancer and other advanced cancers.

ROMANA 1 and ROMANA 2

ROMANA 1 and ROMANA 2 were randomized, double-blind, placebo-controlled Phase 3 trials in patients with non-small cell lung cancer cachexia. Anamorelin produced statistically significant improvements in lean body mass and body weight. The trials did not produce statistically significant improvements in handgrip strength, which was a key functional endpoint (Temel et al., 2016).

The data created a split regulatory profile:

Positive effect on body composition.
Positive effect on appetite and body weight.
Limited proof of improved physical function.
No definitive evidence that the drug changes survival.
No established evidence that it reverses the underlying cancer-cachexia disease process.

Anamorelin’s clinical value is therefore strongest when measured by nutritional status and body composition. Its value is weaker under regulatory frameworks that require demonstrated functional improvement.

European regulatory outcome

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on anamorelin in 2017. The committee concluded that the clinical data did not establish a clinically meaningful benefit because improvements in lean body mass were not accompanied by improvement in muscle strength or physical function (European Medicines Agency, 2017).

That decision materially reduced the probability of near-term European commercialization. A new European filing would likely require a redesigned clinical package with endpoints that connect body composition to functional outcomes and patient benefit.

What is the FDA regulatory status of anamorelin?

Anamorelin has not received FDA approval. It is not an Orange Book-listed U.S. product, and there is no U.S. reference product against which a conventional Abbreviated New Drug Application Paragraph IV challenge can be filed.

The absence of FDA approval has several consequences:

There is no U.S. commercial revenue base.
There is no FDA-recognized regulatory exclusivity period for anamorelin.
There are no Orange Book patent listings for an approved anamorelin product.
U.S. generic entry would depend on a future reference approval or an alternative regulatory strategy.
A U.S. launch would require a sponsor to resolve the efficacy concerns identified in the international program.

The FDA has approved other drugs for appetite stimulation or cancer-related conditions, but those products do not create direct substitutability. Megestrol acetate, corticosteroids, nutritional interventions, and investigational cachexia therapies address overlapping symptoms but have different risk-benefit profiles and mechanisms.

What patents protect anamorelin?

The principal patent protection for anamorelin arose from composition-of-matter and ghrelin receptor agonist patent families developed before Japanese commercialization. The relevant protection is now mature, and the strongest early patent rights are likely to be expired or close to expiration in major jurisdictions.

Publicly available regulatory records do not identify an active U.S. Orange Book patent estate because anamorelin lacks U.S. approval. That distinction is important: patent ownership and regulatory listing are separate issues.

Potential protection categories include:

Protection category	Commercial relevance
Active pharmaceutical ingredient	Likely mature in major jurisdictions
Salt and crystalline forms	May support later expiry dates if valid and enforceable
Pharmaceutical compositions	Can protect tablet manufacture and dosage forms
Cancer-cachexia methods of use	May provide jurisdiction-specific secondary protection
Dosing regimens	May restrict selected treatment schedules
Manufacturing processes	Can create technical barriers without preventing all non-infringing manufacture

The Japanese product’s commercial position depends less on a broad, unexpired composition patent and more on regulatory approval, physician adoption, reimbursement, manufacturing know-how, and the limited number of drugs specifically authorized for cancer cachexia.

A definitive patent-expiry analysis cannot treat every anamorelin-related patent as a product-blocking right. Claims must be reviewed by jurisdiction, legal status, claim scope, prosecution history, supplementary protection rights, and validity risk.

When does anamorelin lose exclusivity?

Japan’s effective commercial exclusivity is not determined by a single U.S.-style Orange Book expiration date. The relevant factors are:

The expiry of core compound claims.
The status of formulation and salt patents.
Any Japanese patent-term adjustment or extension.
Regulatory data-protection rules.
The timing of generic or follow-on product approvals.
Whether a competitor can design around formulation or manufacturing claims.

Because Adlumiz is already marketed in Japan, generic entry risk is higher than for an unlaunched product with a long remaining patent term. The most exposed claims are likely to be broad compound claims. Later-formulation or method-of-use claims may provide narrower protection but are more vulnerable to validity and design-around challenges.

No Paragraph IV litigation exists in the United States because there is no approved U.S. reference product and no Orange Book listing. Any future U.S. patent dispute would likely arise during a new drug application, a post-approval generic filing, or a standalone patent action rather than a current Paragraph IV proceeding.

What is the Japanese market opportunity for Adlumiz?

Japan is the only established commercial market for anamorelin. The opportunity is supported by several factors:

Japan has a large and aging oncology population.
Cancer cachexia is common in advanced gastrointestinal and lung cancers.
Oral administration is convenient for outpatient treatment.
The product has a disease-specific label rather than a general appetite-stimulant positioning.
Treatment is concentrated in four major cancer categories.

The market is constrained by:

Treatment eligibility requirements.
Limited duration of use in advanced disease.
High mortality among target patients.
Variable physician recognition of cancer cachexia.
Need for continued cancer treatment.
Lack of demonstrated improvement in physical function.
Reimbursement and hospital formulary controls.

Japan revenue scenarios

The following is a scenario model rather than a reported company forecast.

Scenario	Treated patients	Annual revenue per patient	Estimated annual sales
Low	20,000	¥300,000	¥6 billion
Base	40,000	¥450,000	¥18 billion
High	60,000	¥600,000	¥36 billion

The base case assumes gradual penetration in eligible patients, recurring treatment over several months, and limited price erosion. A realistic mature range is approximately ¥10 billion to ¥25 billion annually. The high case requires broader screening, stronger evidence of functional benefit, and sustained reimbursement.

Global revenue would remain limited without U.S. or European approval. If a new sponsor obtained approval in the United States and entered selected European markets, a broad commercial range could reach $300 million to $800 million annually. That outcome requires new clinical evidence and should not be treated as the current market consensus.

How does anamorelin compare with competing cachexia therapies?

Anamorelin is differentiated by its oral, targeted ghrelin-receptor mechanism and its Japanese approval. Its main competitors are not direct branded equivalents but include off-label and supportive-care options.

Therapy	Primary effect	Regulatory position	Key limitation
Anamorelin	Appetite, body weight, lean body mass	Approved in Japan	Functional benefit not consistently demonstrated
Megestrol acetate	Appetite and weight gain	Approved in several markets for selected indications	Thromboembolic and steroid-related risks; weight may reflect fat or fluid
Corticosteroids	Short-term appetite and symptom benefit	Widely used off label	Limited durability and substantial adverse effects
Nutritional support	Calorie and protein delivery	Standard supportive care	Does not directly reverse systemic cachexia
Exercise and rehabilitation	Physical function and strength	Supportive intervention	Difficult to implement in advanced disease
Investigational myostatin or activin-pathway drugs	Muscle preservation or gain	Development stage	Mixed clinical and regulatory results

Anamorelin’s competitive advantage is its formal indication and body-composition data. Its disadvantage is the absence of a clearly demonstrated functional endpoint, which weakens health-economic arguments and limits regulatory portability.

What litigation and settlement agreements affect anamorelin?

No major active U.S. patent litigation or Paragraph IV settlement is publicly associated with anamorelin because the product lacks U.S. approval. No broad generic-entry settlement has shaped the current U.S. market.

The principal legal and commercial issues are likely to arise in Japan:

Patent challenges to compound, formulation, or use claims.
Generic applications after loss of enforceable protection.
Disputes over manufacturing routes or crystalline forms.
Licensing and distribution arrangements between Helsinn and Ono.
Regulatory exclusivity and reimbursement rights.

Ono and Helsinn have commercialized anamorelin through a partnership structure. Ono has been responsible for Japanese commercialization, while Helsinn has held development and international rights associated with the product. Public revenue disclosures generally do not isolate Adlumiz sales with enough precision to establish a standalone global revenue trajectory.

How strong is the anamorelin patent estate?

The estate is commercially useful in Japan but does not appear to be a long-duration global barrier.

Strengths

Early patent filings cover a novel ghrelin receptor agonist class.
The product has a differentiated approved use in Japan.
Formulation, salt, and use claims may extend protection beyond the basic compound.
Manufacturing know-how can raise entry costs even after compound patents expire.

Weaknesses

Core patent rights are mature.
No U.S. Orange Book position exists.
European regulatory failure limits the value of European secondary patents.
Method-of-use claims may be narrow and vulnerable to non-infringing indications.
The efficacy profile does not clearly establish broad clinical superiority.

The estate should be characterized as moderate for the Japanese commercial franchise and weak for global blocking power. The main strategic asset is the approved product and clinical data package, not a clearly durable international patent wall.

What generic launch scenarios exist for anamorelin?

A generic or follow-on launch in Japan would likely follow one of three paths.

Early challenge

A competitor challenges remaining formulation or method-of-use claims before broad patent expiry. The competitor argues that the claims are invalid, not infringed, or insufficient to block approval.

Post-expiry entry

A generic enters after the principal enforceable claims expire. Price erosion depends on reimbursement rules, physician switching, tablet substitutability, and the willingness of hospitals to use lower-cost products.

Limited competition

A competitor avoids direct substitution because the Japanese market is too small or because manufacturing and clinical requirements produce unattractive returns. In this scenario, Adlumiz retains meaningful pricing power even after core patents expire.

The most likely commercial result is gradual erosion rather than an immediate, U.S.-style multi-generic collapse. Cancer cachexia is a specialized market, and patient treatment is concentrated among oncology centers.

What licensing and business-development opportunities exist?

Anamorelin offers three possible transaction profiles:

A Japan-focused commercial partnership for hospital sales, reimbursement, and oncology promotion.
A regional development license covering Asia-Pacific markets with similar cachexia burdens.
A global development transaction contingent on a new Phase 3 program.

A global license would carry substantial clinical risk. The buyer would need to fund trials that demonstrate patient-relevant outcomes, such as physical function, activities of daily living, treatment tolerance, or quality of life. Body-weight improvement alone is unlikely to support broad approval in jurisdictions influenced by the EMA precedent.

The asset is more attractive to a company with an established oncology sales force and experience in regulatory rescue programs than to a general generic manufacturer.

What is the investment outlook for anamorelin?

The investment case is asymmetric:

Japan provides validated commercial proof.
International upside is substantial if the endpoint problem is solved.
The current asset has no U.S. revenue and no established EU pathway.
Patent protection is unlikely to provide a long, global period of exclusivity.
Future value depends on clinical redevelopment rather than simple geographic expansion.

A Japan-only valuation should use specialty-pharmaceutical revenue assumptions and account for patent erosion. A global valuation should assign a low-to-moderate probability to successful regulatory redevelopment unless a sponsor has produced new data showing functional benefit.

Key Takeaways

Anamorelin is approved in Japan as Adlumiz for cancer cachexia associated with four cancer types.
The drug increases lean body mass, body weight, and appetite, but functional benefits have not been consistently demonstrated.
The EMA rejected the product because the clinical benefit was not sufficiently meaningful beyond body-composition changes.
Anamorelin is not FDA-approved and has no U.S. Orange Book listing or current Paragraph IV litigation.
Japan is the only established commercial market.
A reasonable mature Japan sales range is ¥10 billion to ¥25 billion annually.
Global sales above $500 million require new clinical evidence and approvals outside Japan.
The patent estate is more valuable as a Japan-specific commercial support than as a durable global barrier.
Generic risk is likely to emerge through Japanese patent expiry, formulation challenges, or specialized follow-on entry.
The central development question is whether anamorelin can demonstrate improved physical function or another regulator-accepted patient-relevant outcome.

FAQs

Is anamorelin approved for cancer cachexia in the United States?

No. Anamorelin has no FDA approval and is not marketed as a U.S. prescription product.

Which cancers are covered by the Japanese Adlumiz label?

The Japanese indication covers cancer cachexia associated with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer, subject to label-specific eligibility requirements.

Why did Europe reject anamorelin?

European regulators concluded that improvements in lean body mass were not matched by convincing improvements in muscle strength or physical function.

Is anamorelin a biosimilar risk?

No. Anamorelin is a small-molecule drug, not a biologic. Competitive entry would involve generic or hybrid-drug pathways rather than biosimilar approval.

Can anamorelin become a billion-dollar drug?

That outcome is unlikely under the current Japan-only profile. It would require successful redevelopment, FDA or European approval, broad reimbursement, and evidence of meaningful functional benefit.

References

European Medicines Agency. (2017). Adlumiz: Withdrawal of the marketing authorisation application. EMA.
Ono Pharmaceutical Co., Ltd. (2020). Adlumiz tablets 50 mg: Japanese prescribing information. Ono Pharmaceutical.
Pharmaceuticals and Medical Devices Agency. (2020). Review report: Anamorelin hydrochloride hydrate. PMDA.
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, J., Yan, Y., & Fearon, K. C. H. (2016). Anamorelin in patients with non-small-cell lung cancer and cachexia: Results from two randomised, double-blind, phase 3 trials. The Lancet Oncology, 17(4), 519-531.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

US Patents	0
International Patents	0
US Patent Applications	152
WIPO Patent Applications	54
Japanese Patent Applications	16
Clinical Trial Progress	Phase 3 (2018-12-18)
Vendors	45

Investigational Drug Information for Anamorelin

What is the drug development status for Anamorelin?

Summary for Anamorelin

Recent Clinical Trials for Anamorelin

Clinical Trial Summary for Anamorelin

Top disease conditions for Anamorelin

Top clinical trial sponsors for Anamorelin

US Patents for Anamorelin

Anamorelin Development Update, Patent Position, and Market Projection